First Solar 10-Qquarter ended 2026-09-30

Executive Summary

First Solar manufactures thin-film cadmium telluride solar modules and earns revenue by selling them to solar-project customers. It is expanding U.S. manufacturing and improving module technology, positioning itself around domestic-production incentives and customers’ demand for U.S.-made equipment. Q3 sales fell 23%, but manufacturing incentives lifted profitability as module shipments weakened. Contracted deliveries provide multiyear visibility, yet cancellations, changing trade rules and delayed conversion of credits into cash make backlog quality and cash generation more important than headline earnings alone.

What's Happening in the Business

First Solar’s U.S. expansion advanced while sales lagged production. Its fifth U.S. factory recently began operating, and phase one of its sixth facility, in South Carolina, started commercial production in 09/2026. The latter completes modules initiated overseas; management expects phase two in mid-2027. Greater U.S. production supports manufacturing-credit eligibility but also carries higher production costs.

International manufacturing faces a tougher environment: low-priced Chinese competition in Europe, Indian restrictions on Southeast Asian products and U.S. import tariffs are prompting a realignment of Series 6 production. Management expects new U.S. minimum import prices, effective 12/4/2026, to improve future sales volumes, pricing and contract terms, although other policy changes could undermine customers’ project economics.

Technology investment continues alongside expansion. An Ohio facility converted to the CuRe technology program in H1, with Indian production expected in Q1 2027; a perovskite pilot line is expected in 2027. These investments seek better-performing products, but premature power loss in some older Series 7 modules has already hurt pricing and generated warranty claims.

Key Financial Highlights

• Production and shipments: Q3 output reached 4.3 GW, +19%, while sales volume fell 22% to 4.1 GW. Finished-goods inventory increased 65% from year-end to $726M, tying up cash as factories expanded.
• Incentive support: Government grants reduced cost of sales by $638M in Q3 vs $396M, and $1.50B in 9M vs $1.08B. Section 45X manufacturing credits were the principal margin driver; Q3 gross margin reached 57.9% vs 38.3%.
• Earnings versus cash: Government-grant receivable movements consumed $1.29B of operating cash. Capital spending of $435M brought 9M FCF to $(837)M vs $117M; this reflects collection timing and working-capital investment, not just weaker sales.
• Liquidity: Cash and cash equivalents fell 44% from year-end to $1.58B after investment and debt repayments. Debt carrying value fell 78% to $108M, all current, while a new $1.5B unsecured revolving facility was undrawn.
• Research spending: 9M R&D rose 26% to $210M, reflecting staffing, equipment, depreciation and an impairment of equipment removed from the technology roadmap.

Risk Assessment

• Policy and overseas assets: Changes to manufacturing credits, solar-project incentives and trade rules could simultaneously reduce domestic profitability, weaken customer demand and leave international factories underused or impaired.
• Contract enforceability: Customers have breached or renegotiated agreements, and some trade-policy clauses permit cancellation without liability or require deposit refunds; the BP Solar and Lightsource nonpayment lawsuit illustrates that contracted revenue is not assured.
• Product quality: Estimated future losses on affected 2023–2024 Series 7 modules are $40M–$65M, against a $46M specific liability; further deterioration could increase claims and price concessions.
• Cash timing and commitments: Growing incentive receivables and inventory constrain cash while expansion continues, and specified substrate-glass commitments carry potential termination payments up to ≈$300M.
• Tax dispute: The Internal Revenue Service proposed a $721M increase in taxable income for 2016–2021—not a tax bill; an adverse resolution could materially change the tax provision.
• Patent litigation: Expanding TOPCon patent disputes bring uninsured litigation costs and the possibility that adverse rulings weaken First Solar’s intellectual-property rights.

This 10-Q lists only the risk factors that changed since the annual report. Full list: the company's 10-Ks on SEC.

What to Watch

• Contract conversion: Backlog covers 44.0 GW and $13.5B through 2030. Deliveries without substantial renegotiations would validate visibility; cancellations, refunds or lost pricing adjustments would weaken it.
• U.S. factory ramp: South Carolina’s first phase is operating. Timely phase-two commissioning and increased sales would validate expansion; inventory accumulation or underutilization would undermine it.
• Technology and reliability: Indian CuRe production and the perovskite pilot are expected in 2027. Successful launches and contained Series 7 claims would support competitiveness; delays or larger warranty provisions would challenge it.
• Cash recovery: Grant receivables stand at $1.87B. Collections and improving operating cash flow would validate earnings quality; continued accumulation would increase reliance on liquidity facilities.